Amgen Files Patent Infringement Suit Over Cholesterol Drug

Amgen Files Patent Infringement Suit Over Cholesterol Drug

Amgen Inc. said last Friday that it has filed a patent-infringement lawsuit against Regeneron Pharmaceuticals Inc. and Sanofi over their experimental cholesterol drug, alirocumab.
The suit, filed in the U.S. District Court of Delaware, comes as Amgen and Regeneron and Sanofi race to be the first to get their cholesterol drugs to the market. The suit alleges that Regeneron and Sanofi are violating three Amgen patents with alirocumab, one of an emerging group of medicines that lower cholesterol by targeting a gene known as PCSK.